http://pharmalicensing.com/rss/ Latest market and business intelligence from the leading publishers worldwide. en-us http://pharmalicensing.com/rss/ http://pharmalicensing.com/images/pharmalicensing_logo.jpg 144 BEVERLY HILLS, Calif., Aug. 3, 2010 -- OXIS INTERNATIONAL, INC. (OTC Bulletin Board: OXIS, Paris: OXI) announced today the launch of its wholly owned subsidiary, Oxis Consumer Products (OCP),... http://pharmalicensing.com/redirs/news_rss//public/news/view/530725/2/0/oxis-international-inc-oxis-announces-the-launch-of-oxis-consumer-products-subsidiary http://pharmalicensing.com/redirs/news_rss//public/news/view/530725/2/0/oxis-international-inc-oxis-announces-the-launch-of-oxis-consumer-products-subsidiary September 01, 2010 -- Stefan Brinkmann, Managing Director of Nycomed GmbH, kicked off the German market launch of Daxas http://pharmalicensing.com/redirs/news_rss//public/news/view/531026/2/0/from-oranienburg-to-the-rest-of-the-world-global-market-launch-of-daxas http://pharmalicensing.com/redirs/news_rss//public/news/view/531026/2/0/from-oranienburg-to-the-rest-of-the-world-global-market-launch-of-daxas Basel, 1 September 2010 - Straumann, a global leader in implant, restorative and regenerative dentistry today announced the initial market launch of its new CADCAM dental restoration system, which... http://pharmalicensing.com/redirs/news_rss//public/news/view/530911/2/0/straumann-launches-new-cadcam-dental-restoration-system http://pharmalicensing.com/redirs/news_rss//public/news/view/530911/2/0/straumann-launches-new-cadcam-dental-restoration-system Malvern, PA, [September 1, 2010] - Neuronetics, Inc., maker of the NeuroStar TMS (Transcranial Magnetic Stimulation) Therapy http://pharmalicensing.com/redirs/news_rss//public/news/view/530872/2/0/neuronetics-selected-by-world-economic-forum-as-2011-technology-pioneer http://pharmalicensing.com/redirs/news_rss//public/news/view/530872/2/0/neuronetics-selected-by-world-economic-forum-as-2011-technology-pioneer Sydney, Australia and Bedminster, New Jersey -August 31, 2010 -QRxPharma (ASX: QRX and OTCQX: QRXPY) announced today it will sponsor a symposium at the IASP (International Association for the... http://pharmalicensing.com/redirs/news_rss//public/news/view/530898/2/0/qrxpharma-to-sponsor-symposium-at-international-association-for-the-study-of-pain-meetings http://pharmalicensing.com/redirs/news_rss//public/news/view/530898/2/0/qrxpharma-to-sponsor-symposium-at-international-association-for-the-study-of-pain-meetings Berlin, Germany, August 31, 2010 - The Phase III EINSTEIN-DVT clinical trial of the oral anticoagulant rivaroxaban demonstrated non-inferiority compared to the standard of care for the prevention... http://pharmalicensing.com/redirs/news_rss//public/news/view/530731/2/0/bayer http://pharmalicensing.com/redirs/news_rss//public/news/view/530731/2/0/bayer NEW YORK, N.Y. - August 31, 2010 - Medidata Solutions (NASDAQ: MDSO), a leading global provider of SaaS-based clinical development solutions, today announced that PharmaNet Development Group has... http://pharmalicensing.com/redirs/news_rss//public/news/view/530743/2/0/pharmanet-joins-medidata-solutions-cro-partner-program http://pharmalicensing.com/redirs/news_rss//public/news/view/530743/2/0/pharmanet-joins-medidata-solutions-cro-partner-program Irvine, California - August 31, 2010 - Masimo (NASDAQ: MASI) announced today that a new randomized controlled trial published in Anesthesia & Analgesia shows that clinicians using Masimo Pleth... http://pharmalicensing.com/redirs/news_rss//public/news/view/530746/2/0/randomized-controlled-trial-finds-masimo-pvi-improves-fluid-management-during-surgery http://pharmalicensing.com/redirs/news_rss//public/news/view/530746/2/0/randomized-controlled-trial-finds-masimo-pvi-improves-fluid-management-during-surgery Stockholm, SE (August 31, 2010) -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), announced today that the investigational, oral anticoagulant rivaroxaban successfully... http://pharmalicensing.com/redirs/news_rss//public/news/view/530750/2/0/rivaroxaban-successfully-demonstrated-non-inferiority-compared-to-standard-of-care-for-the-prevention-of-recurrent-venous-thromboembolism-in-pivotal-phase-3-study http://pharmalicensing.com/redirs/news_rss//public/news/view/530750/2/0/rivaroxaban-successfully-demonstrated-non-inferiority-compared-to-standard-of-care-for-the-prevention-of-recurrent-venous-thromboembolism-in-pivotal-phase-3-study San Diego, August 31, 2010 - Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the commercial launch of its proprietary PROMETHEUS http://pharmalicensing.com/redirs/news_rss//public/news/view/530766/2/0/prometheus-launches-the-first-serogenetic-test-to-predict-risk-of-complications-from-crohns-disease http://pharmalicensing.com/redirs/news_rss//public/news/view/530766/2/0/prometheus-launches-the-first-serogenetic-test-to-predict-risk-of-complications-from-crohns-disease